Oral Cancer News | Tag Archive

New DNA therapy for advanced mouth cancer

Sunday, February 7, 2010

Source: www.dentistry.co.uk Author: staff A research team has been awarded a patent after developing a new DNA therapy for head and neck cancer sufferers. Researchers from the University of Pittsburgh School of Medicine in the US, aims to develop a safe and effective alternative to standard chemotherapy treatments which cause debilitating side-effects. Based on a form of [...]

Pitt researchers receive patent for new head and neck cancer treatment

Sunday, January 31, 2010

0 Comments

Source: www.healthcanal.com Author: staff Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many types of [...]

Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer

Tuesday, November 17, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study were [...]

YM Biosciences reports positive nimotuzumab four-year survival data

Tuesday, November 3, 2009

0 Comments

Source: www.reuters.com Author: press release YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its EGFR-targeting antibody, [...]

Erbitux® may improve treatment of squamous cell carcinoma of the esophagus

Saturday, October 3, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1] Esophageal cancer is relatively common and is very deadly. [...]

Tips on managing the rash associated with EGFR inhibitors

Monday, September 28, 2009

0 Comments

Source: OncologySTAT (www.oncologystat.com) Author: OncologySTAT Editorial Team Nurses at Duke University Hospital in Durham, NC, have developed a treatment algorithm for the rash that frequently occurs with use of epidermal growth factor receptor (EGFR) inhibitors. “We want to help sustain patients so they can continue to get their therapy and maintain their quality of life,” Kimberly Bishop, [...]

Gefitinib shows promise as treatment for advanced head and neck cutaneous squamous cell carcinoma

Wednesday, July 15, 2009

0 Comments

Source: www.docguide.com Author: Louise Gagnon Gefitinib produces a significant response in patients with advanced head and neck cutaneous squamous cell carcinoma (cSCC) prior to standard treatment, according to a phase 2 study presented here at the 2nd World Congress of the International Academy of Oral Oncology (IAOO). “We want to shrink the tumour as much as we can [...]

Vanderbilt-Ingram Cancer Center’s research efforts highlighted at annual cancer conference

Saturday, June 27, 2009

0 Comments

Source: www.mc.vanderbilt.edu Author: Dagny Stuart A new drug which targets a genetic mutation found in more than 50 percent of melanoma cases, 10 percent to 15 percent of colorectal tumors and 8 percent of other solid tumors, caused tumor shrinkage and extended progression-free survival among patients during a recent Phase 1 clinical trial. Igor Puzanov, M.D., assistant [...]

DNA therapy for head and neck cancer

Tuesday, June 2, 2009

0 Comments

Source: Nature Reviews Clinical Oncology 6, 302 (June 2009) Author: Mandy Aujla Researchers have developed an antisense EGFR sequence to target EGFR, and found that this approach was safe and effective in patients with advanced squamous-cell carcinoma of the head and neck. Standard treatment for this type of cancer is suboptimal. Various drugs have been developed to block [...]

Personalised cancer diagnosis

Wednesday, May 13, 2009

0 Comments

Source: www.economist.com Author: staff If researchers could identify what it is that makes a tissue tumorous, they might be able to develop drugs aimed precisely at the cause of the cancer. At present, they know that certain molecules become active in tumours found in certain parts of the body. Both head-and-neck cancers and breast cancers, for example, [...]

Tag Archive | "EGFR"